TW202115114A - 針對靶向ｂ細胞成熟抗原的多特異抗體之給藥方案及組合療法 - Google Patents

針對靶向ｂ細胞成熟抗原的多特異抗體之給藥方案及組合療法 Download PDF

Info

Publication number
TW202115114A
TW202115114A TW109121083A TW109121083A TW202115114A TW 202115114 A TW202115114 A TW 202115114A TW 109121083 A TW109121083 A TW 109121083A TW 109121083 A TW109121083 A TW 109121083A TW 202115114 A TW202115114 A TW 202115114A
Authority
TW
Taiwan
Prior art keywords
use according
dose
subject
administered
therapeutic
Prior art date
Application number
TW109121083A
Other languages
English (en)
Chinese (zh)
Inventor
金伯利 艾達倫
艾達 艾柏喬
約翰 布藍肯錫
安娜拉達 康納
麥爾克 多斯泰萊克
湯尼 佛雷明
康妮 洪
布萊恩 霍姆柏格
綠 黃
海慧 呂
Ｋ 蓋瑞 Ｊ 凡奈斯
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202115114A publication Critical patent/TW202115114A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109121083A 2019-06-24 2020-06-22 針對靶向ｂ細胞成熟抗原的多特異抗體之給藥方案及組合療法 TW202115114A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962865381P 2019-06-24 2019-06-24
US62/865,381 2019-06-24
US201962940589P 2019-11-26 2019-11-26
US62/940,589 2019-11-26
US202062967401P 2020-01-29 2020-01-29
US62/967,401 2020-01-29
US202063034106P 2020-06-03 2020-06-03
US63/034,106 2020-06-03

Publications (1)

Publication Number Publication Date
TW202115114A true TW202115114A (zh) 2021-04-16

Family

ID=71738213

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109121083A TW202115114A (zh) 2019-06-24 2020-06-22 針對靶向ｂ細胞成熟抗原的多特異抗體之給藥方案及組合療法

Country Status (10)

Country Link
US (1) US20220332821A1 (https=)
EP (1) EP3986569A1 (https=)
JP (2) JP2022538237A (https=)
KR (1) KR20220024729A (https=)
CN (2) CN119679936A (https=)
AU (1) AU2020307471A1 (https=)
CA (1) CA3144324A1 (https=)
IL (1) IL289187A (https=)
TW (1) TW202115114A (https=)
WO (1) WO2020261093A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US20200179511A1 (en) * 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
LT3819007T (lt) 2019-11-11 2024-10-10 Amgen Research (Munich) Gmbh Dozavimo režimas, skirtas anti-bcma agentams
JP2023524875A (ja) 2020-05-11 2023-06-13 ヤンセン バイオテツク，インコーポレーテツド 多発性骨髄腫を治療するための方法
BR112022021956A2 (pt) * 2020-05-13 2022-12-13 Pfizer Métodos, terapias e usos para o tratamento de câncer
CA3206543A1 (en) * 2021-01-29 2022-08-04 Shanghai Hansoh Biomedical Co., Ltd. Antibody-drug conjugate and medical use thereof
CN115521381B (zh) * 2021-06-24 2024-10-29 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
WO2023284806A1 (zh) * 2021-07-14 2023-01-19 江苏恒瑞医药股份有限公司 特异性结合cd38、bcma和cd3的抗原结合分子及其医药用途
CN113908395B (zh) * 2021-10-13 2024-05-17 科悦医疗(苏州)有限公司 一种促醒仪
MX2024005392A (es) * 2021-11-03 2024-08-06 Janssen Biotech Inc Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3.
CN121712524A (zh) * 2023-08-18 2026-03-20 百时美施贵宝公司 包含结合bcma和cd3的抗体的组合物以及治疗方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
GB0120347D0 (en) 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
KR100838852B1 (ko) 2003-09-09 2008-06-16 에프. 호프만-라 로슈 아게 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체
CA2544350A1 (en) 2003-10-29 2005-05-12 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
ATE535614T1 (de) 2003-12-30 2011-12-15 Kowa Co Screening-verfahren fuer gamma-sekretase- inhibitoren
DK1730119T3 (da) 2004-03-23 2008-08-11 Pfizer Prod Inc Imidazolforbindelser til behandling af neurodegenerative forstyrrelser
WO2007019232A2 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
EP1984321A1 (en) 2006-02-17 2008-10-29 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
EP2011513B1 (en) 2006-04-25 2016-10-19 The University of Tokyo Therapeutic agents for alzheimer's disease and cancer
WO2009020579A1 (en) 2007-08-07 2009-02-12 Schering Corporation Gamma secretase modulators
JP5385904B2 (ja) 2007-08-14 2014-01-08 イーライ リリー アンド カンパニー γ−セクレターゼ阻害剤
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
WO2013066740A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Gamma secretase modulators
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP2925313A4 (en) 2012-11-29 2016-05-11 Merck Sharp & Dohme SPIROCYCLIC SULPHONES AS GAMMA SECRETASE INHIBITORS
TW201625692A (zh) * 2014-11-14 2016-07-16 諾華公司 抗體藥物結合物
EP3223907A2 (en) * 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
PE20171324A1 (es) * 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
TWI703159B (zh) 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
WO2017019496A1 (en) 2015-07-24 2017-02-02 Berenson James Richard Gamma secretase modulators for the treatment of immune system dysfunction
WO2017136562A2 (en) * 2016-02-02 2017-08-10 Kadmon Corporation, Llc Bispecific binding proteins for pd-l1 and kdr
JP7267914B2 (ja) * 2016-11-02 2023-05-02 エンクマフ エスアーエールエル Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
US20200179511A1 (en) * 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
KR102870868B1 (ko) * 2018-06-01 2025-10-15 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도

Also Published As

Publication number Publication date
US20220332821A1 (en) 2022-10-20
JP2022538237A (ja) 2022-09-01
KR20220024729A (ko) 2022-03-03
WO2020261093A1 (en) 2020-12-30
CN119679936A (zh) 2025-03-25
JP2025138634A (ja) 2025-09-25
IL289187A (en) 2022-02-01
AU2020307471A1 (en) 2022-01-27
CN114286828A (zh) 2022-04-05
EP3986569A1 (en) 2022-04-27
CA3144324A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
TW202115114A (zh) 針對靶向ｂ細胞成熟抗原的多特異抗體之給藥方案及組合療法
US11529399B2 (en) Anti-ICOS agonist antibodies and uses thereof
TWI799432B (zh) 抗ctla-4抗體及其用途
CN114929343B (zh) 用双特异性抗BCMA x抗CD3抗体治疗多发性骨髓瘤的方法
CN112384534A (zh) 用于增强nk细胞对靶细胞的杀死的组合物和方法
JP7335164B2 (ja) 抗ｔｉｇｉｔ抗原結合タンパク質及びその使用方法
TW202128759A (zh) 結合ｎｋｇ２ｄ、ｃｄ及ｆｌｔ３之蛋白質
JP7274426B2 (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
CN106068275A (zh) 抗pd‑1的人抗体
CN108235685A (zh) Pd-1拮抗剂与egfr抑制剂的组合
JP2021503911A (ja) 抗ｏｘ４０抗体及びその用途
IL295471A (en) Anti-bcma therapy in autoimmune disorders
US20230140694A1 (en) Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
CN115244084A (zh) 抗gitr抗体及其用途
US20240124607A1 (en) Proteins binding nkg2d, cd16, and ceacam5
TW202400228A (zh) 減輕細胞激素釋放症候群的給藥方案
JP2025516772A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを用いて巨細胞性動脈炎を治療する方法
BR112016022381B1 (pt) Anticorpo humanizado isolado ou fragmento de ligação ao antígeno deste que se liga ao receptor canabinóide 1 (cb1), uso do mesmo, composição farmacêutica e método in vitro de agonizar ou antagonizar cb1